Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Antares, Benevira, Biomx, Blade, CASI, Clearmind, Dongcheng, Galapagos, Genocea, Halozyme, Insilico, Imaginab, Journey, Kalivir, Knight, Padagis, Rigel, Roche, RS, Scipher, Scisparc, Synthonics, Sparrow, Tianshi, ZZ.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Abbvie, Alnylam, Antengene, Armata, Aurinia, Biond, Chinook, Compass, Concert, Day One, Hansa, Idorsia, Janssen, Liminal, Neurocrine, Pfizer, Polypid, Rapt, Regeneron, Salubris, Saniona, Seagen, Stealth, Tenax, Teva, UCB, Visen.

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Alcon, Aptamer, Cantargia, Catalyst, Elicio, Entasis, Immunocore, Immunome, Innoviva, Kala, Lupagen, Medison, Mirum, Pharmacyte, Pinotbio, Quoin, Satiogen, St. Jude, Umoja and Vertex.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Aileron, Aldeyra, Argenx, Athersys, Avalo, Axsome, Belief, Bridgebio, Enanta, Foghorn, Healios, Insmed, IO Biotech, Lipidor, Menarini, Lysogene, Mustang, Ocuphire, Qlaris, Radius, Recce, Regencell, Rocket, Scilex, Tricida, Ultragenyx, Zealand.

After listing on the Nasdaq market on May 18, Hong Kong-based diagnostics and genetic testing company Prenetics Group Ltd. saw its shares fall nearly 30% in early trading, dropping from $8.40 per share on listing to $5.70 by the end of trading May 19. Trading under the ticker PRE, Prenetics formed a merger with Artisan Acquisition Corp., a special purpose acquisition company, which was founded by entrepreneur Adrian Cheng. The transaction values Prenetics at an enterprise value of $1.25 billion, making the company the first Hong Kong unicorn to list on the Nasdaq.

Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Anika, Nanomix, Trinity Biotech.

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Abbvie, Biontech, Eiger, Eli Lilly, Indaptus, Karyopharm, Merck, Mersana, Mirati, Novartis, Pfizer, Poxel, PTC, Saniona, Sanofi, Siga, Simcere, Tallac, Tetra, Umecrine, Valneva.

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Akari, Almac, Aslan, Biogen, Blue Water, Comera, Hitgen, Immix, Kymera, Smart Immune, Tenaya and Zymeworks.

The Biden administration recently reported that a new round of free rapid tests for the SARS-CoV-2 virus is available to the public, a development that coincides with a new surge of the latest sub-variant of the omicron variant. However, the administration is also expected to renew the public health emergency (PHE) for the pandemic, even as the White House continues to press Congress for another $22 billion in pandemic-related funding.